{
    "Clinical Trial ID": "NCT00976989",
    "Intervention": [
        "INTERVENTION 1: ",
        "  T+P Concomitant Anthracycline-based Chemotherapy",
        "  5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.",
        "INTERVENTION 2: ",
        "  T+P Sequential Anthracycline-based Chemotherapy",
        "  FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  female participants, age >/=18 years",
        "  advanced, inflammatory or early stage unilateral invasive breast cancer",
        "  HER2-positive breast cancer",
        "  baseline left ventricular ejection fraction (LVEF) >/=55%",
        "Exclusion Criteria:",
        "  metastatic disease (Stage IV) or bilateral breast cancer",
        "  previous anticancer therapy or radiotherapy for any malignancy",
        "  other malignancy, except for carcinoma in situ of the cervix, or basal cell carcinoma",
        "  clinically relevant cardiovascular disease",
        "  current chronic treatment with corticosteroids of >10mg methylprednisolone or equivalent"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator",
        "  Left ventricular systolic dysfunction (LVSD) as assessed by the Investigator, including Grade 3, 4 or 5 symptomatic LVSD with symptomatic cardiac events.",
        "  Time frame: From baseline up to approximately 3.5 years",
        "Results 1: ",
        "  Arm/Group Title: T+P Concomitant Anthracycline-based Chemotherapy",
        "  Arm/Group Description: 5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.",
        "  Overall Number of Participants Analyzed: 72",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  0",
        "Results 2: ",
        "  Arm/Group Title: T+P Sequential Anthracycline-based Chemotherapy",
        "  Arm/Group Description: FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.",
        "  Overall Number of Participants Analyzed: 75",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  2.7"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 23/72 (31.94%)",
        "  Febrile Neutropenia 10/72 (13.89%)",
        "  Neutropenia 2/72 (2.78%)",
        "  Leukopenia 2/72 (2.78%)",
        "  Thrombocytopenia 0/72 (0.00%)",
        "  Left ventricular dysfunction 1/72 (1.39%)",
        "  Cardiovascular disorder 0/72 (0.00%)",
        "  Conduction disorder 0/72 (0.00%)",
        "  Diarrhoea 1/72 (1.39%)",
        "  Vomiting 0/72 (0.00%)",
        "  Nausea 0/72 (0.00%)",
        "  Small intestinal obstruction 0/72 (0.00%)",
        "Adverse Events 2:",
        "  Total: 18/75 (24.00%)",
        "  Febrile Neutropenia 4/75 (5.33%)",
        "  Neutropenia 3/75 (4.00%)",
        "  Leukopenia 0/75 (0.00%)",
        "  Thrombocytopenia 0/75 (0.00%)",
        "  Left ventricular dysfunction 3/75 (4.00%)",
        "  Cardiovascular disorder 0/75 (0.00%)",
        "  Conduction disorder 0/75 (0.00%)",
        "  Diarrhoea 3/75 (4.00%)",
        "  Vomiting 2/75 (2.67%)",
        "  Nausea 1/75 (1.33%)",
        "  Small intestinal obstruction 0/75 (0.00%)"
    ]
}